The Event Brings Together Leaders in Bio Pharma, AI, and Clinical Development for a Day of Insightful Panel Conversations and Networking Experiences

BOSTON: QuantHealth, an AI-powered clinical trial design company, today is welcoming over 100 attendees for their first AI in Clinical Development Summit, slated to be the cornerstone of innovation in the biotechnology industry. This Summit is set to bring together thought leaders from various sectors of the healthcare ecosystem to explore the transformative potential of artificial intelligence in revolutionizing drug development.

The Summit presents a dynamic lineup of discussions and panels, where industry titans and experts will delve into the applications of AI in clinical development. Attendees can expect insightful conversations on various topics surrounding AI, including its use in early and late stages of clinical trials, venture investment in emerging technology for clinical development, AI in clinical operations and its evolving regulatory landscape. The programming of the Summit is designed to address critical questions and challenges in the field and provide networking opportunities to connect attendees with industry leaders from Sanofi, Microsoft, Moderna, Harvard, and more.

“This Summit cultivates a dynamic environment to encourage creative collaboration among influential stakeholders within the healthcare and technology domains.” said Orr Inbar, CEO and Co-Founder of QuantHealth. “By bringing together key players from both sectors, we aim to facilitate the exchange of insights, expertise, and innovative ideas. Together, we will propel the field of drug development forward by harnessing the power of AI-driven technologies.”

Christian Hein, former VP, Global Head of Digital Transformation & Innovation Execution at Novartis adds, "AI has the potential to revolutionize every stage of drug development, from target identification to clinical trials. By leveraging AI-driven insights, we can enhance efficiency, reduce costs, and ultimately bring life-saving treatments to patients faster. This Summit provides a platform to exchange ideas and best practices, driving innovation forward."

From exploring the applications of AI throughout drug development to delving into regulatory considerations and investment opportunities, each panel at The AI in Clinical Development Summit offers unique insights into the intersection of AI and healthcare. With esteemed C-Suite attendees and a robust agenda focused on collaboration and innovation, this Summit sets the stage for groundbreaking advancements that are poised to revolutionize the future of medicine.

“Generative AI is capturing the attention of the healthtech industry, but how to use these applications in a reliable, ethical way presents numerous challenges and potential complications,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. “Collaboration within the field is critical as we work to navigate these obstacles and identify areas where AI can add the most value. By bringing together some of the brightest minds in the bio pharma, AI, and clinical trial industry, we are advancing more than just the narrative around AI in healthcare, we are increasing our potential for success.”

About QuantHealth

90% of drugs fail the clinical stage, representing a direct $45B annual waste to pharma companies. To address this challenge at its core, QuantHealth's Clinical-Simulator predicts how each patient in a clinical trial will respond to treatment, allowing trial design teams to predict how an entire clinical trial will play out and adapt accordingly. Based on its novel AI engine and a vast dataset of 350m patients and over 700K therapeutics, QuantHealth's simulator can predict clinical trial results with high accuracy, allowing users to answer mission-critical questions such as trial go/no-go, cohort optimization, drug repurposing, and more. QuantHealth was founded by healthcare experts who led commercial, product, and data science at various leading companies in the US and Israel. QuantHealth is backed by expert Life-Science investors in the US, Europe, and Israel and is supported by an advisory board of physicians and scientists from leading academic institutions. To learn more, visit https://quanthealth.ai/.

Fonte: Business Wire